Medical statistics
- or -
Post a project like this$$
- Posted:
- Proposals: 0
- Remote
- #2119605
- Expired
Description
Experience Level: Intermediate
Q1 Suppose that you were to re-design the IPASS trial as a superiority trial, with rate of survival at 1 year as primary endpoint.Suggest, based on published evidence, what percentages (referred to as P1 and P2 in the lecture slides) you would consider in the sample size calculation. Recalculate the sample size (i.e. write down the equation and populate it with the right numbers) and give the total sample size (i.e. for the two arms together).
A
Me
6:29 PM
Q2 Within IPASS, treatment was given until progression. Given that IPASS demonstrated that Gefitinib is non-inferior to the current standard, justify how you would design (noninferiority, or equivalence or superiority trials) a proposed follow up phase III trial to IPASS, designated IPASS2, to investigate the optimum duration of Gefitinib.
A
Me
6:29 PM
Q2 Within IPASS, treatment was given until progression. Given that IPASS demonstrated that Gefitinib is non-inferior to the current standard, justify how you would design (noninferiority, or equivalence or superiority trials) a proposed follow up phase III trial to IPASS, designated IPASS2, to investigate the optimum duration of Gefitinib.
Ariun N.
0% (0)Projects Completed
-
Freelancers worked with
-
Projects awarded
0%
Last project
20 Apr 2024
United Kingdom
New Proposal
Login to your account and send a proposal now to get this project.
Log inClarification Board Ask a Question
-
There are no clarification messages.
We collect cookies to enable the proper functioning and security of our website, and to enhance your experience. By clicking on 'Accept All Cookies', you consent to the use of these cookies. You can change your 'Cookies Settings' at any time. For more information, please read ourCookie Policy
Cookie Settings
Accept All Cookies